Trial Profile
A Phase 4, Open-label, Multicenter, Prospective Study to Evaluate the Effect of Remission Status on the Ability to Maintain or Achieve Clinical and Endoscopic Remission During a 12-Month, Long-term Maintenance Phase With 2.4g/Day MMX Mesalamine/Mesalazine Once Daily in Adult Subjects With Ulcerative Colitis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Dec 2021
Price :
$35
*
At a glance
- Drugs Mesalazine (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms MOMENTUM
- Sponsors Shire
- 01 Jul 2021 Results of post-hoc assessing changes in clinical, endoscopic, and histologic disease activity are uniquely associated with meaningful changes in HRQoL for patients with UC following disease treatment, published in the Quality of Life Research.
- 10 Oct 2018 Results presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2018
- 01 Jan 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.